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Brain white matter hyperintensities (WMHs) are a prevalent MRI feature of healthy and pathological states in older age, and are associated with important life outcomes (Debette and Markus, 2010; Kloppenborg et al 2014; Lee et al., in press; Longstreth et al., 1996) , and with vascular risk factors (VRFs) such as hypertension, diabetes, smoking, obesity, and hypercholesterolemia (de Leeuw et al., 2004; Dufouil et al., 2001; Wardlaw et al., 2014; Prins and Scheltens, 2015; Wang et al., 2015) . Compared with cross-sectional WMH volumetric measures, WMH progression shows a stronger relation with important age-related functional changes (Prins and Scheltens, 2015; van Dijk et al., 2008) , and it is possible that different VRFs are relevant at different ages (Zhang et al., 2015) . Hence, longitudinal studies with a narrow age-range are essential to identify the most pertinent VRFs at specific periods in life.
Alongside evidence of VRF-WMH associations, WMH heritability is estimated at 55-80% (Carmelli et al., 1998; Atwood et al., 2004; Turner et al., 2004) . Variation in the apolipoprotein E (APOE) gene (which delivers essential lipids to neurons, and is linked to accelerated neurodegeneration Bu, 2009; Mahley and Rall, 2000) , is a plausible candidate to explain some of this heritability. Possession of the e4 'risk' allele is associated with more WMHs and poorer white matter microstructure in older adults (Brickman et al., 2014; Heise et al., 2011) , and greater cognitive decline (Schiepers et al., 2012; Wisdom et al., 2011; Bangen et al., 2013) . However, APOE was not associated with cross-sectional WMH load in two large studies (Paternoster et al., 2009; Fornage et al., 2011) . Discrepancies between heritability estimates of complex disease and the risk explained by common genetic variants might be due to interactions with VRFs (Manolio et al., 2009) . Prior examinations of APOE-VRF interactions involved M A N U S C R I P T
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cross-sectional white matter measures across participants of a broad age range, yielding inconsistent results (de Leeuw et al., 2004; Wang et al., 2015; Foley et al., 2014) .
The current study is the first, to our knowledge, to test interactions between APOE e4 status and VRFs on longitudinal WMH progression.
Materials & Methods

Participants
Members participants provided written informed consent and these have been kept on file.
APOE status
Genotyping on the two polymorphic sites (rs7412 and rs429358) that account for the e2, e3 and e4 alleles (Wenham et al., 1991) 
Vascular Risk Factors
The World Heart Federation, UK National Health Service, Framingham Heart Study, and the British Heart Foundation (Web References 2-5) overlap in their identification of diabetes, hypertension, smoking, high body mass index (BMI) and hypercholesterolemia as important VRFs, and are pertinent to WMH burden in older age (de Leeuw et al., 2004; Dufouil et al., 2001; Wardlaw et al., 2014; Prins and Scheltens, 2015; Wang et al., 2015) . VRFs were assessed during a cognitive and physical testing appointment at age 73 years. During a medical interview, diagnosis of diabetes, hypertension, smoking (current, ex, or never) and hypercholesterolemia were reported. Objective VRFs were: BMI (weight kg / height m 2 ), pulse pressure (difference between average systolic and diastolic blood pressure, taken over six consecutive measurements, three sitting, three standing, from an Omron 705IT monitor); blood glycated haemoglobin (HbA1c using a Menarini HA8160 analyser); the ratio of high density lipoprotein to total cholesterol (HDL ratio; Milián et al., 2009 ).
MRI Acquisition & Processing
Whole brain MRI was performed on each participant at ages 73 and 76 years using the same scanning protocol in the same scanner (GE Signa Horizon 1.5 T HDx; Milwaukee, WI, USA). T1-, T2-, T2*-and FLAIR-weighted sequences were co-registered at a resolution of 1 × 1 × 2 mm. A semi-automated multispectral fusion method (Valdés Hernández et al., 2010) combined these sequences to measure intracranial (ICV) and WMH volume. WMHs were explicitly defined as punctate, focal or diffuse lesions in all subcortical regions (Wardlaw et al., 2013) . All segmented images were visually examined for accuracy on anonymised scans to correct errors and ensure that infarcts (including lacunar infarcts, n=3 at baseline in this sample) and enlarged perivascular DCCT), visualised and tested (t-tests) group differences in WMH progression.
Results
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Participant characteristics are shown in Table S1 , and density plots of the raw and corrected measures of WMH change are shown in Figure 1 . There was a significant increase in corrected WMH volume in under 4 years (t (865.34) = 3.685, p < 0.001) in the total sample. Associations among the VRFs were modest (Table S2) and showed low VIF (all <1.87) . Exploratory factor analysis provided no basis to extract one (χ 2 = 164.8, p = 8.85×10 -25 ; 18.4% of the variance) or two (χ 2 = 59.96, p = 5.33×10 -8 ; 27.9% of the variance) factors of general vascular risk. One hundred and thirty-six participants were APOE e4 carriers, who were not significantly different to non-e4 carriers in terms of age, cross-sectional WMH volume at either wave, male:female ratio, MMSE score at Wave 2, or VRF status. APOE e4 carriers did, however, show a significantly lower MMSE score at Wave 3 (p = 0.020, Table S1 ).
Effects of VRFs on WMH volume change -without reference to APOE -have previously been reported in this sample (Dickie et al., 2016) . The main effects are therefore reported here for illustrative purposes, but the focus of the current analyses is specifically to examine VRF-APOE interactions on WMH progression. Main effects of APOE and VRFs on WMH volume change, and their interaction, are reported in Table   1 . APOE e4 carriers and those with a lower HDL ratio showed nominally greater WMH progression than non-e4 carriers (β = 0.118, p = 0.014 and β = -0.101, p = 0.034, respectively), but these did not survive FDR correction.
Participants with either a self-reported diagnosis of diabetes (β = 0.160, p = 0.002) or higher HbA1c (β = 0.114, p = 0.014) showed greater WMH progression, but only for APOE e4 carriers. Only the interaction between APOE e4 and diabetes survived FDR correction. Correcting these relationships for other, co-occuring VRFs (BMI, hypertension and hypercholesterolaemia based on Table S2 ), did not substantially alter the interaction effects for diabetes (β = 0.167, p < 0.001) and HbA1c (β = 0.118, p = M A N U S C R I P T
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8 0.008). Further group-wise analysis showed that participants with diabetes, or high HbA1c, who carried the APOE e4 allele exhibited significantly greater change in WMH volume progression over 3.7 years than all other groups (all t-values >2.34; Figure 1 ).
Discussion
The present study tested whether APOE status interacted with important VRFs in contributing to WMH volume change from age 73 to 76 years in a large group of community-dwelling older adults with a narrow age range. Our novel results suggest that WMH growth was greater in those with diabetes and a higher HbA1c, but only in those who possessed an APOE e4 allele, though only the former interaction survived FDR correction.
The finding that APOE e4 is associated with WMH progression extends previous cross-sectional associations between APOE status and WMH volume in older age (de Leeuw et al., 2004; Wang et al., 2015; Brickman et al., 2014) . Rather than being an index of the degree to which APOE status relates to accumulated WMH burden up to a specific (single) point of assessment, the current data suggest that carrying the e4 allele continues to influence the degree of WMH progression at this specific age. In isolation, diabetes was not associated with WMH progression (consistent with previous studies; Prins and Scheltens, 2015) , but, importantly, we found that those with a current diagnosis of diabetes showed significantly greater WMH progression, but only if they carried the APOE e4 allele. The effect size was similar for an objective measure of glycaemic control, but this finding did not survive FDR correction. These findings are consistent with prior associations between diabetes risk -including glycaemic control in 'pre-diabetes' -and APOE allele status for cognitive decline and dementia (Irie et al., 2008; Dore et al., 2009; Peila et al., 2002; Roriz-Filho et al., 2009) . Taken together, this evidence provides support for the hypothesis that, as with other complex diseases, M A N U S C R I P T
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genetic interactions are important for understanding relationships between VRFs and WMH progression in older age, and identifying potential targets for amelioration of brain ageing and dementia.
The duration, level and success of medical intervention for VRF-control in the current sample (such as statins for hypercholesterolemia, anti-hypertensive or antidiabetic medication) is unknown, and may affect these findings. We also relied upon self-report for information on a variety of clinical diagnoses. Nevertheless, the use of blood biomarkers such as HDL ratio and HbA1c allow objective measures, independent of self-report for some VRFs. More importantly, although the current total sample is relatively large, the proportion of individuals with both diabetes and the e4 allele was small, thus the specific diabetes-APOE interaction effect should be tested independently. However, the presence of the same interaction (with similar magnitude)
with HbA1c might ostensibly corroborate the biological plausibility of this result.
Having only two waves of data makes our results more susceptible to artefacts such as regression to the mean (see Nesselraode, Stigler & Baltes, 1980) and other sources of bias such as measurement error. Our use of FIML in this relatively large sample can only guard against these possibilities to some degree. Finally, some sample characteristics limit the confidence with which these findings can be generalised to groups of different ages, ethnicities, and pathological states. Nevertheless, these sample characteristics can also be viewed as study strengths, as they attenuate important potential confounds of age, ethnicity and the effect of infarcts on WMH measurement, offering valuable insights into specific age and interactions that might influence the progression of structural brain damage.
The reduction of average blood glucose levels is identified here as a potentially meaningful predictor of WMH progression in the mid-70s among APOE e4 carriers. 
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This work requires replication in other larger prospective imaging studies, and also at different ages to examine whether, and which, interactions contribute to life-course WMH volume changes. Furthermore, APOE is only one of many potential genetic contributors to WMH burden in older age. Its consistent association with dementia and cognitive decline make it an obvious candidate for interaction studies, but WMH risk is likely to be polygenic (Lopez et al., 2015) , and future studies should examine other genetic-VRF interactions for predicting WMH volume and progression. Caption: Kernel density plots of white matter hyperintensity progression, split by APOE status are shown for a) raw uncorrected change in mm 3 , calculated by subtraction, and b) WMH change calculated as the residuals of the regression between age 73 and 76 volumes, which were each log transformed and corrected for ICV and age at scan. A score of zero therefore denotes average WMH change in this and subsequent panels. The lower panels show group differences in corrected WMH change split by APOE status and c) selfreported diabetes diagnosis and d) HbA1c level. Groups created from the whole sample based on a median split of HbA1c (Low range 4.4 -5.59 DCCT, High range 5.60 -8.9 DCCT), and APOE e4 status (carriers versus non-carriers). Brackets indicate significant group differences at * p < 0.05, ** p < 0.01, *** p < 0.001. Bold horizontal lines represent group means, vertical lines denote standard error. • WMHs were measured at age 73 and age 76 in community dwelling older adults.
• We measured self-reported and objective measures of vascular risk factors (VRFs).
• These included hypertension, diabetes, cholesterol, smoking and body mass index.
• APOE e4 carriers with diabetes and poorer glycaemic control had greater WMH growth.
